Ofatumumab for Post-Transplant Lymphoproliferative Disorder

Authors

Madhav Seshadri, Division of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA b New YorkFollow
Genevieve M. Crane, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA
Usama Gergis, Department of Medical Oncology, Division of Hematological Malignancies, Sidney Kimmel Cancer Center, Philadelphia, PA, USA

Abstract

Posttransplant lymphoproliferative disorder (PTLD) includes a range of abnormal lymphoid proliferation following solid organ or allogeneic hematopoietic stem cell transplantation (HSCT), often associated with EpsteineBarr virus (EBV) infection. Treatment generally incudes rituximab, a chimeric monoclonal antibody directed against CD20. Here we present a 56-year-old woman with EBV-associated PTLD following allogeneic HSCT who was intolerant of rituximab. The patient was instead treated with ofatumumab, a fully human monoclonal antibody directed against CD20, with significant response in EBV viral load and lymphadenopathy. Ofatumumab could represent an important treatment option for patients unable to tolerate rituximab.

Recommended Citation

Seshadri, Madhav; Crane, Genevieve M.; and Gergis, Usama (2022) "Ofatumumab for Post-Transplant Lymphoproliferative Disorder," Hematology/Oncology and Stem Cell Therapy: Vol. 15 : Iss. 1 , Article 12.
Available at: https://doi.org/10.1016/j.hemonc.2020.04.004

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.